PVRL2Poliovirus Receptor-Like 2
References in periodicals archive ?
2028) includes data showing higher expression of PVRL2, the ligand for PVRIG, compared to expression of PVR, the ligand for TIGIT, in tumor types that include breast, endometrial, and ovarian cancers.
According to the company, COM701 is a humanized hybridoma antibody that binds with high affinity to PVRIG, a novel B7/CD28-like immune checkpoint target candidate, blocking its interaction with PVRL2.